TG 003,
TG-003,
TG003 cpd,
TG003,
TG 003,
300801-52-9,
719277-26-6,
TG-003,
Clk inhibitor,
Clk Inhibitor, TG003,
(Z)-1-(3-ethyl-5-methoxybenzo[d]thiazol-2(3H)-ylidene)propan-2-one,
(Z)-1-(3-Ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one,
CHEMBL408982,
(1Z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one,
Cdc2-Like Kinase Inhibitor, TG003,
Cdc2-Like kinase inhibitor,
SR-01000076048,
MFCD00624584,
AC1LZ6CO,
1-(3-Ethyl-5-methoxy-3H-benzothiazol-2-ylidene)-propan-2-one,
MLS000077198,
GTPL5942,
SCHEMBL2977826,
2-Propanone, 1-(3-ethyl-5-methoxy-2(3H)-benzothiazolylidene)-, (1Z)-,
EX-A683,
BGVLELSCIHASRV-QPEQYQDCSA-N,
HMS2355I17,
HMS3229E10,
HMS3262D10,
ZINC4793192,
Tox21_500894,
2753AH,
BDBM50026622,
s7320,
STK874212,
AKOS000546683,
CCG-204976,
LP00894,
SB19460,
NCGC00032387-02,
NCGC00032387-03,
NCGC00032387-04,
NCGC00032387-05,
NCGC00032387-06,
NCGC00032387-07,
NCGC00261579-01,
BAS 00107536,
BC600729,
BP-20670,
SMR000001066,
TG003, >=98% (HPLC),
RT-011952,
EU-0100894,
SW219950-1,
K00243,
J-017766,
SR-01000076048-1,
SR-01000076048-2,
BRD-K97072811-001-07-2,
BRD-K97072811-001-09-8,
1-(3-ethyl-5-methoxy-2(3H)-benzothiazolylidene)-2-propanone,
(1Z)-1-(3-Ethyl-5-methoxy-2(3H)-benzothiazolylidene)-2-propanone,
1-[3-Ethyl-5-methoxy-3H-benzothiazol-(2Z)-ylidene]-propan-2-one,
(1Z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2(3H)-ylidene)propan-2-one,
(Z)-1-(3-ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene) propan-2-one,
719277-26-6; 300801-52-9(mix E/Z); 1164521-02-1 (E),
TG003 cpd,
D06MBI,
C13H15NO2S,
CID1893668,
C487497,
1-(3-Ethyl-5-methoxybenzo[d]thiazol-2(3H)-ylidene)propan-2-one,
(1~{Z})-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one,